| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9119876 | PAR STERILE PRODUCTS | Epinephrine formulations |
Mar, 2035
(10 years from now) | |
| US9295657 | PAR STERILE PRODUCTS | Epinephrine formulations |
Mar, 2035
(10 years from now) | |
| US10130592 | PAR STERILE PRODUCTS | Epinephrine formulations |
Mar, 2035
(10 years from now) | |
| US11083698 | PAR STERILE PRODUCTS | Epinephrine compositions and containers |
Mar, 2039
(14 years from now) | |
| US11207280 | PAR STERILE PRODUCTS | Epinephrine compositions and containers |
Mar, 2039
(14 years from now) | |
| US10653646 | PAR STERILE PRODUCTS | Epinephrine compositions and containers |
Mar, 2039
(14 years from now) | |
Adrenalin is owned by Par Sterile Products.
Adrenalin contains Epinephrine.
Adrenalin has a total of 6 drug patents out of which 0 drug patents have expired.
Adrenalin was authorised for market use on 18 December, 2013.
Adrenalin is available in solution;intravenous, solution;intramuscular, intravenous, subcutaneous dosage forms.
Adrenalin can be used as emergency treatment of allergic reactions (type i), including anaphylaxis, to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock.
The generics of Adrenalin are possible to be released after 21 March, 2039.
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 18 December, 2013
Treatment: Emergency treatment of allergic reactions (type i), including anaphylaxis; To increase mean arterial blood pressure in adult patients with hypotension associated with septic shock
Dosage: SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS; SOLUTION;INTRAVENOUS
ADRENALIN family patents
